Forte Biosciences, Inc. (FBRX)
Aug 27, 2026 - FBRX was delisted (reason: acquired by ARGX)
76.99
0.00 (0.00%)
Inactive · Last trade price on Aug 26, 2026
Company Description
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases.
The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials.
Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.
Forte Biosciences, Inc.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Paul A. Wagner |
Contact Details
Address: 3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 United States | |
| Phone | 310 618 6994 |
| Website | fortebiorx.com |
Stock Details
| Ticker Symbol | FBRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1419041 |
| CUSIP Number | 34962G208 |
| ISIN Number | US34962G2084 |
| Employer ID | 26-1243872 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul A. Wagner Ph.D. | Chief Executive Officer, President and Chairman |
| Antony A. Riley CPA | Chief Financial Officer |
| Dr. Barbara K. Finck M.D. | Senior Medical Clinician and Director |
| Christopher Roenfeldt | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 27, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 27, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 27, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 27, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |